Cargando…

A clinical variable‐based nomogram could predict the survival for advanced NSCLC patients receiving second‐line atezolizumab

OBJECTIVE: A nomogram model based on clinical variables was conducted to predict the survival in patients with non‐small cell lung cancer (NSCLC) receiving second‐line atezolizumab. METHODS: Four hundred and twenty‐four patients with NSCLC receiving atezolizumab from OAK study were regarded as the t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shang, Xiaoling, Shi, Jianxiang, Wang, Xiaohui, Zhao, Chenglong, Yu, Haining, Wang, Haiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446569/ https://www.ncbi.nlm.nih.gov/pubmed/34331414 http://dx.doi.org/10.1002/cam4.4160

Ejemplares similares

A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab
por: Lin, Jiamao, et al.
Publicado: (2021)

A Novel Nomogram including AJCC Stages Could Better Predict Survival for NSCLC Patients Who Underwent Surgery: A Large Population-Based Study
por: Shang, Xiaoling, et al.
Publicado: (2020)

Incorporating the Number of PLN into the AJCC Stage Could Better Predict the Survival for Patients with NSCLC: A Large Population-Based Study
por: Shang, Xiaoling, et al.
Publicado: (2020)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab
por: Nie, Wei, et al.
Publicado: (2020)

Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
por: Gandara, David, et al.
Publicado: (2021)

Different distant metastasis patterns based on tumor size could be found in extensive-stage small cell lung cancer patients: a large, population-based SEER study
por: Li, Jia, et al.
Publicado: (2019)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
por: Ryu, Rachel, et al.
Publicado: (2018)

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
por: Chang, John Wen-Cheng, et al.
Publicado: (2022)

A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study
por: Shan, Qinge, et al.
Publicado: (2021)

PLNR≤20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study
por: Shang, Xiaoling, et al.
Publicado: (2018)

A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis
por: Ikeda, Satoshi, et al.
Publicado: (2020)

Development and validation of nomogram to predict risk of survival in patients with laryngeal squamous cell carcinoma
por: Cui, Jie, et al.
Publicado: (2020)

Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment
por: Su, Po‐Lan, et al.
Publicado: (2019)

A hypothesized TNM staging system based on the number and location of positive lymph nodes may better reflect the prognosis for patients with NSCLC
por: Shang, Xiaoling, et al.
Publicado: (2019)

A gene expression signature‐based nomogram model in prediction of breast cancer bone metastases
por: Zhao, Chenglong, et al.
Publicado: (2018)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
por: Tovoli, Francesco, et al.
Publicado: (2021)

Development and validation of a nomogram to predict synchronous lung metastases in patients with ovarian cancer: a large cohort study
por: Yuan, Yufei, et al.
Publicado: (2020)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Development and validation of a nomogram for assessing survival in patients with hepatocellular carcinoma after hepatectomy
por: Huo, Rong-Rui, et al.
Publicado: (2020)

Development and validation of a nomogram to predict the prognosis of patients with squamous cell carcinoma of the bladder
por: Hu, Mei-Di, et al.
Publicado: (2019)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
por: Wang, Yingcheng, et al.
Publicado: (2021)

Intratumor heterogeneity is associated with less CD8(+) T cell infiltration and worse survival in patients with small cell lung cancer
por: Zhang, Chenyue, et al.
Publicado: (2022)

Cellular Therapy in NSCLC: Between Myth and Reality
por: Imbimbo, Martina, et al.
Publicado: (2023)

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
por: Friedman, Claire F, et al.
Publicado: (2020)

Analysis of chemotherapy effect on the second primary malignancy for head and neck cancer patients by a nomogram based on SEER database
por: Li, Xinrong, et al.
Publicado: (2020)

Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial
por: Salem, Riad, et al.
Publicado: (2021)

Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
por: Remon, Jordi, et al.
Publicado: (2020)

Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study
por: Zhou, Yongjian, et al.
Publicado: (2023)

Increased risk of second primary malignancies among endometrial cancer survivors receiving surgery alone: A population‐based analysis
por: Lai, Yen‐Ling, et al.
Publicado: (2021)

Association between microRNA-146a, -499a and -196a-2 SNPs and non-small cell lung cancer: a case–control study involving 2249 subjects
por: Qiu, Hao, et al.
Publicado: (2021)

Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
por: Moliner, L., et al.
Publicado: (2023)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
por: Wan, Ning, et al.
Publicado: (2020)

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer
por: Hellmann, Matthew D., et al.
Publicado: (2020)

HbA1c Variability and Cardiovascular Events in Patients with Prostate Cancer Receiving Androgen Deprivation Therapy
por: Chan, Jeffrey Shi Kai, et al.
Publicado: (2022)

Commentary on: Nomograms based on inflammatory biomarkers for predicting tumor grade and microvascular invasion in stage I/II hepatocellular carcinoma
por: Xiao, Liang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0iv638go3p2oji48qriot2c68u